Now in its 13th year, TEC VenturePrize is an annual business plan competition for early stage Alberta technology entrepreneurs.
For over a decade, VenturePrize participants have shown proven success, making VenturePrize and TEC Edmonton recognized as key drivers of Alberta economic diversification.
Participants submit their business plans and compete for a prize package of cash and in-kind services to help grow their companies. The Fast Growth Grand Prize Winner receives over $80,000 in cash and in-kind services, and the two Runners-Up receiver over $30,000 in cash and in-kind services.
Alieo Games is an educational technology company that recently launched COW, a writing app for students and teachers in K-12. COW provides a safe and fun space for students to practice writing (building writing fluency and vocabulary) and to share their work with classmates. For teachers, COW uses text analysis to provide useful feedback that they can use to customize their lesson plans to meet the specific needs of their students.
Alieo Games tells a great story of University of Alberta student innovation that has already succeeded in winning several business competitions. Their writing app COW is being used by students in grades 2-10.
Pogo CarShare is Edmonton’s first car sharing service. Founded and managed locally, Pogo provides members 24/7 access to a pool of vehicles located within a central zone in our city on a simple pay-as-you-go basis. Cars can be located, reserved and opened using the Pogo app. Customers only pay for the exact amount of time they use the vehicle, and gas, insurance, parking, and maintenance are all included in the flat, per-minute rate.
Convenient, affordable and environmentally sustainable, Pogo CarShare introduces a greater freedom of transportation options to Edmontonians, and is estimated to increase public transportation use by three times per week.
Sensassure is a wearable tech startup that was founded as part of Canada’s Next 36, a national tech incubator program. Sensassure’s sensor solution for the incontinent elderly tracks if they’ve wet themselves and alerts nursing staff when changes are required. Sensassure helps restore dignity to those who suffer from incontinence by automating existing manual care processes, leading to timely changes that prevent secondary conditions from developing.
Sensassure’s technology addresses the ever present needs of senior care and provides an innovative new technology to improve quality of care – one that can also be used in a home setting.
Winners of the TEC VenturePrize Fast Growth, Student and TELUS Information & Communication Technology (ICT) competition streams will be announced at the VenturePrize Awards Celebration on April 29, 2015, at the Edmonton Shaw Conference Centre.
The event brings together the region’s business and innovation community, highlighting the next generation of Alberta’s technology entrepreneurs.
Starting April 1st, the public will be able to vote for their favorite Fast Growth Finalist online. The winner will receive the Edmonton Journal People’s Choice Award, also to be presented at the VenturePrize Awards Event on April 29.
For more information on VenturePrize, or to purchase tickets for the VenturePrize Awards Celebration, visit www.ventureprize.com.
Phone: (780) 248-5886
TEC Edmonton’s Technology Management team offers expert advice on intellectual property matters which often lead to new patents, licensing agreements and company spin-offs.
Bacterial Endotoxin for the Prevention of Metabolic Disorders and Bacterial Infections Researcher: Dr. Burim Ametaj
Ruminant diets rich in starch lead to the development of metabolic disorders by changing the gastrointestinal microflora from fibre-digesting bacteria to starch-digesting bacteria. These starch-digesting bacteria, mostly Gram-negative bacteria, release large amounts endotoxins that are translocated into the host’s blood circulation triggering multiple perturbations associated with a variety of periparturient diseases such as ketosis, fatty liver, laminitis, displaced abomasum, milk fever, downer cow syndrome, udder edema, metritis, retained placenta, infertility and mastitis.
The University of Alberta researcher discovered that oral administration of Gram-negative bacterial endotoxin or lipopolysaccharide to dairy cows during the dry off period was effective in preventing the development of several of the those diseases.
TEC Edmonton and Innovate Calgary have embarked on a unique partnership. With funding from the federal government’s Canada Accelerator and Incubator Program (CAIP), the two city-based technology business accelerators are supporting each other in offering province-wide technology accelerator programs in their respective areas of expertise.
TEC Edmonton’s TEC Health Accelerator concentrates on growing Alberta’s new and early-stage health-related companies, in building bridges between those companies and the Canadian health industry, investors and Alberta’s health delivery system. The University of Alberta is known for its health-related research and commercialization opportunities. Metropolitan Edmonton also has a cluster of off-campus health-related technology companies.
Kinetica, using a slightly different business model, will enhance linkages between energy-related small-to-medium-sized enterprises, startup companies, investors and the industry at large.
Kinetica is using a push-pull model, says Kinetica program director Kevin Frankowski, finding out what the energy industry is looking for, developing a “shopping list”, scouting for new companies with solutions, assessing and mentoring such companies toward commercialization of their product.
Kinetica’s focus areas within the energy sector are hydrocarbon recovery, energy transport, carbon capture/re-use/disposal and renewables.
“Industry wants de-risked, field-trial ready solutions for their key challenges,” Frankowski told the audience gathered at the introduction. “Our job is to shorten the traditionally long development cycle of such products, to guide our Kinetica clients through the ‘valley of death’ (scale up, testing, pre-field trials, then pilot and field trials) leading to commercial use.”
For Kinetica to take an early-stage company into its program, the company must have a product, service or solution on the “challenge list” that Kinetic is compiling from the industry.
The candidate company must be at a “beyond-concept”. Commercialization must be a top priority and a prime motivation.
Kinetica is not, stressed Frankowski, a technology developer, broker, venture fund or industry association. It scouts for companies with solutions to energy industry needs, then guides and mentors those companies on the path to commercialization and profitability.
To learn more about Kinetica’s programs and mandate, visit kineticaventures.com. or contact Kinetica’s Northern Alberta representative Lorena Forester at 780-966-4809, email@example.com.
University of Alberta researchers can learn more about the program through TEC Edmonton Technology Management VP Jayant Kumar, firstname.lastname@example.org, 780-492-9806.
Led by TEC Edmonton in partnership with Innovate Calgary, the TEC Health Accelerator is a new initiative designed to accelerate the growth of Alberta biotechnology companies and connect community entrepreneurs with medical and scientific researchers in Alberta. The program also bridges the gap between investors, Alberta startup companies, Alberta Health Services (AHS), potential industry partners and large animal/health agriculture companies. By connecting these entities, TEC Health Accelerator aims to broker major financing, partnership deals and revenue growth for clients in the healthcare space.
Janssen Inc. is a leading healthcare company that offers innovative products in areas of high unmet medical need like oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.
A division of Johnson & Johnson Inc., Johnson & Johnson Medical Products markets medical devices and diagnostic solutions for use by health-care professionals and hospitals in Canada. The portfolio includes medical devices for minimally invasive and open surgical procedures, devices for women’s health, infection prevention and control, cardiovascular and neurovascular diagnostics and treatment, and breast implants for augmentation and reconstruction.
“We’re very excited to partner with Janssen and Johnson & Johnson Medical Products and their proven track record for top quality medical products and services,” said Chris Lumb, TEC Edmonton CEO. “Their support of TEC Health Accelerator means better ways to connect the Alberta health and business communities.”
Named 2014 “Incubator of the Year” by Startup Canada and “10th Best University Business Incubator in the World” by the 2014 University Business Index (UBI), TEC Edmonton launched the new TEC Health Accelerator on November 27, 2014.
For more information, visit www.tecedmonton.com or contact:
The staff of TED Edmonton joins so many in Alberta’s innovation and academic communities in mourning the sudden passing of Dr. Cy Frank, CEO of Alberta Innovates Health Solutions (AIHS).
“We at TEC Edmonton are feeling incredibly saddened by the news of Dr. Cy Frank’s passing on March 5,” says TEC Edmonton CEO Chris Lumb.
“Cy was a highly respected leader in the health community. In addition to being a clinician, he was known for his work in building community support for system change and optimization of health delivery practices. He demonstrated this by leading changes that resulted in vastly improved efficiency and health outcomes in orthopaedic surgery in the province. Cy was in the midst of leading broader change through his role at Alberta Innovations Health Solution.
“Alberta’s health system will miss Cy’s visionary leadership.”
Caring for wounds costs the Canadian health care system $3.9 billion a year. TEC Centre tenant Exciton has a solution that’s helping people around the world. Global’s health reporter Su-Ling Goh explains.
TEC Edmonton client NanoSpeed just released a news announcement for the expansion of its global distribution agreement with DiaSys Diagnostics Systems. http://www.businesswire.com/news/home/20150302006240/en/NanoSpeed-Announces-Global-Distribution-Partnership-DiaSys-Diagnostics#.VPYkL_nF_lE
Rakesh Soni of LoginRadius (TEC Centre tenant, TEC Edmonton client and TEC VenturePrize past finalist) was recently interviewed on CBC Radio’s Edmonton AM.
NanoSpeed Announces Global Distribution Partnership with DiaSys Diagnostics Systems for Test4D™
Edmonton, Alberta — (March 2, 2015) – NanoSpeed Diagnostics, Inc. (“NanoSpeed”) is pleased to announce an expansion of their exclusive distribution agreement with global diagnostics and instrumentation distributor, DiaSys Diagnostics Systems GmbH (“DiaSys”), to market their 25-OH Vitamin D deficiency test kit. Under the broadened agreement, DiaSys will market the point-of-care vitamin D test under their own brand, QDx™, worldwide except in those territories that are already part of NanoSpeed’s network and certain other territories. DiaSys is a large point-of-care diagnostics technology company with locations in Europe, Asia and Latin America selling to over 100 countries.
“An important element of positioning our point-of-care vitamin D test to meet the needs of patients is having broad and diverse distribution,” said Dr. Seema Gupta, President of NanoSpeed Diagnostics, Inc., a leading diagnostics company focused on providing portable, innovative and rapid testing solutions. “DiaSys has tremendous global reach and an unparalleled passion for safe and high-quality tests to bring the best result for patients. This agreement is an important milestone for our company and patient access to our vitamin D test. We would like to acknowledge the assistance of TEC Edmonton for their business development support.”
Technical support, advisory services and financial support from the National Research Council of Canada Industrial Research Assistance Program (“NRC-IRAP”), along with the contributions from Western Economic Diversification and Alberta Innovates – Technology Futures, were crucial to the success of NanoSpeed and its products.
NanoSpeed’s vitamin D test is a patented and unique point-of-care test that provides information on Vitamin D deficiency within 10 minutes. This test requires only a single drop of blood from the patient and costs 90% less when compared to other standard or conventional tests.
Test4D® and QDx™ are not approved for commercial use in Canada or the United States and is limited by federal law to research or investigational use only.
About DiaSys Diagnostics Systems GmbH
DiaSys Diagnostic Systems is a leading specialist in the development and manufacturing of diagnostic system solutions of highest quality, trusted by customers in more than 100 countries for over 20 years. Our product portfolio comprises more than 90 clinical chemistry and immunoturbidimetric reagents for routine and special diagnostics including suitable calibrators and controls. The DiaSys instrumentation product range covers automated clinical chemistry analyzers, semi-automated analyzers and point of care (POC) instruments for near-patient testing.
DiaSys decided to focus further into POC: this strategic investment with global intent includes R&D, manufacturing and a portfolio of solutions, recently presented, under the QDx brand.
NanoSpeed, incorporated in 2009, develops proprietary diagnostic/screening test kit platforms based on their Lateral Flow Immuno Assay and Lab-on-a-Chip technologies. These technological advancements provide patients with cost effective and reliable testing tools that will address the increasing needs of the healthcare industry, regulatory agencies and consumers.
About Vitamin D deficiency and Test4D™:
Vitamin D deficiency is a common problem in Canada, where 60% of adults have suboptimal levels of 25-OH vitamin D. Vitamin D deficiency has been associated with abnormalities in absorption of calcium, phosphorus, and bone metabolism; cardiovascular disease; diabetes; cancer; osteomalacia and osteoporosis in adults; and rickets in children. Deficient vitamin D levels are typically the result of an inadequate intake of vitamin D through sunlight, diet, or supplements, or due to malabsorptive disorders.
25-OH vitamin D levels are currently measured through laboratory testing. Over the past decade, there has been an incremental surge in the demand for vitamin D testing, resulting in increasing costs to government supported healthcare systems. An alternative to laboratory testing is Point-of-Care-Testing (POCT), medical testing that occurs outside of a clinical laboratory and near the patient. Potential advantages of POCT include reduction in errors and costs to the healthcare system, and the provision of quick clinical diagnoses.
To address the demands of vitamin D testing, NanoSpeed Diagnostics Inc. developed Test4D™, a POCT device for the qualitative detection of 25-OH Vitamin D in human blood obtained via fingertip puncture.
Test4D™ is available for commercial sale through certain distributors, or can be purchased for research purposes directly from NanoSpeed.
A Point-of-Care Diagnostic Tool to Replace Chest X-Ray for the Diagnosis of Childhood Pneumonia
Description University of Alberta researchers have discovered a novel set of biomarkers which can be used to diagnose pneumonia in children. The biomarkers include chitinase-3-like-1 (CHI3L1), lipocalin-2 (LCN-2), C-reactive protein......
Novel Cell Isolation Method for Bio-engineering Artificial Cartilage
Description University of Alberta researchers have developed a new method to isolate cells from knee joint (meniscus). The isolated cells are non-contractile in nature and do not form scar tissue.......
Novel Composite Monolith as a New Solid Phase Extraction Material for Environmental Analysis
Description University of Alberta researchers have developed a new material of a composite silica monolith nested in sponge (SiMNS) for solid phase extraction. The application of the new SiMNS material......
Self Assembling Peptide for Activating Human Mast Cells
Description Researchers at the University of Alberta have developed a novel biomaterial that can activate the body’s own innate immune response and accelerate the wound healing process. This technology may......
An Innocuous Structured Scaffold for Prion Disease Vaccines and Antigens
Description Researchers at the University of Alberta, led by Dr. Holger Wille, have developed a novel strategy for the creation of vaccines and specific antigens for prion protein diseases. Applying......
Description Demonstration of stereotactic setup. An example of a commercially-available micromanipulator is shown. The setup can accommodate any micromanipulator design. Dr. Vivian Mushahwar and her team have developed an image-guided......
Method for the Production of Z-Olefins from 1,3-Dienes
Description Dr. Rylan Lundgren has developed a process for formate-mediated production of Z-olefins (also referred to as cis-alkenes) in the presence of a rhodium-based catalyst. The process is highly selective......
A Novel Method to Produce Pitched Kefir for Reducing Cholesterol
Description Researchers at the University of Alberta and TEAGASC have jointly developed a pitched-based method to produce kefir (a fermented milk beverage) that when consumed reduces blood cholesterol levels. The......
Novel F-18 Beta-Hydroxybutyric Acid Radiotracers for PET Imaging
Description Researchers at the University of Alberta have synthesized novel beta-hydroxybutyric acid radiotracers for PET imaging using a 3 step radiosynthetic process. The compounds are designed to serve as radiofluorinated......
A Novel Method for CryoPreservation of Cells in Monolayers
Description Researchers at the University of Alberta have developed a novel method to cryopreserve cells while adhered in a monolayer configuration. This method can preserve cells on a substrate and......
Train-Triggered Alert System for Conditioning and Warning Wildlife
Description Researchers at the University of Alberta have developed a novel, inexpensive, and compact system to alert wildlife to approaching trains, increasing the time available to avoid a collision. Rail-caused......
Description Dr. Afsaneh Lavasanifar and collaborators have developed a PCBCL–b-PEG-b-PCBCL (PolyGelTM) hydrogel formulation of silibinin which provides enhanced skin permeabiity and delayed release of silibinin under physiological conditions. In vitro......